4/7/2014 8:59:40 AM
NEW YORK, April 7, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that preclinical data for TGR-1202, the Company's novel PI3k delta inhibitor will be highlighted at the 105th American Association for Cancer Research (AACR) Annual Meeting taking place April 5-9, 2014 in San Diego, California.
Help employers find you! Check out all the jobs and post your resume.
comments powered by